Gilead Sciences Inc: (NASD: GILD)

$56.36

0.11 (0.20%)

Volume 16,625,910

May 15 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		55.09 - 57.10
	
		52wk Low - High
		24.12 - 57.10
	
		Previous Close
		56.25
	
		Avg. Volume
		13,600,373
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		85.72 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.51
	
		PE (Forward)
		29.60
	
		Current Year Est.
		1.90
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		79 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/6/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            29.60
                        
                            PEG Ratio
                            1.13
                        
                            Current Year Est.
                            1.90
                        
                            Current Quarter Estimate
                            0.47
                        
                            Most Accurate Estimate
                            0.47
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-25-2013
                        
                            EPS Last Year
                            1.88
                        
                            Expected Earnings Growth
                            26.23%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.   
Full GILD Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
GILD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.47	0.47	1.90	2.76
Number of Estimates	3	3	3	3
Low Estimate	0.46	0.44	1.83	2.36
High Estimate	0.47	0.48	1.96	NA
Year Ago EPS	0.47	0.47	1.73	1.90
EPS Growth	-0.71%	-1.75%	9.83%	45.26%

More GILD Estimates

Average Earnings Estimates for GILD

EPS Growth for GILD

Industry Analysis

Name	Symbol	Previous Close
GILEAD SCIENCES	GILD	56.25
AETERNA ZENTARS	AEZS	1.91
ALKERMES INC	ALKS	31.35
ANIKA THERAPEUT	ANIK	14.10
GENTIUM SPA-ADR	GENT	8.67
NOVELOS THERAPT	NVLT	0.46
TRANZYME INC	TZYM	0.58
AASTROM BIOSCI	ASTM	0.60
ACHILLION PHARM	ACHN	7.30
AFFYMAX INC	AFFY	1.42

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Stock Market News for May 14, 2013

May 14, 2013

Stock Market News for May 13, 2013

May 13, 2013

Gilead Misses on Earnings, Sales in 1Q

May 03, 2013

Double Setback for Gilead

Apr 30, 2013

Is the Biotech Sector Still a Market Leader?

Apr 25, 2013

Gilead Reports Encouraging HCV Data

Apr 24, 2013

Will Eli Lilly Beat Earnings in 1Q?

Apr 23, 2013

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, Eli Lilly, Gilead Sciences and Logitech International

Apr 23, 2013

More GILD Zacks Commentary

Financials

EPS TTM	1.88
Sales	9,703
Net Income	2,872
Price/Earnings	30.00
Price/Book	8.25
Price/Cash Flow	28.26
Price/Sales	8.61

More GILD Financials

News

Gilead Sciences (GILD) Showing Bullish Technicals But Could Break Through $57.51 Resistance - Freshbrewedmedia

May 15, 2013

Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15 - Businesswire

May 14, 2013

Racing Toward the Next Hepatitis C Drug Approval - TheMotleyFool

May 14, 2013

Reveal Insider Trading in J.C. Penney, Gilead Sciences, Chesapeake Energy, Annaly Capital Management, Endo Health Solutions, and Zynga - Pr Newswire

May 14, 2013

Should You Buy Stock in Gilead After the Earnings Miss? - TheMotleyFool

May 14, 2013

Buyers Accumulate Shares of Gilead Sciences, Up 2.3% - Financial News Network Online - Market Movers

May 13, 2013

The 8 Biggest Health Problems Americans Face - TheMotleyFool

May 13, 2013

3 Investment Strategy Lessons From Vertex`s Success - TheMotleyFool

May 11, 2013

See All News Stories on GILD

Broker Recommendations

Current ABR	1.38
ABR (Last Week)	1.39
# of recs in ABR	21
Average Target Price	58.88
Industry Rank by ABR	79 out of 265
Rank in Industry	33 out of 156

More GILD Broker Recommendations

Day Low - High	55.09 - 57.10
52wk Low - High	24.12 - 57.10
Previous Close	56.25
Avg. Volume	13,600,373
Industry	MED-BIOMED/GENE
Market Cap	85.72 B
Div - Yield	0.00 - 0.00
Beta	0.51
PE (Forward)	29.60
Current Year Est.	1.90
Quarterly Earnings ESP	0.00%

PE (Forward)	29.60
PEG Ratio	1.13
Current Year Est.	1.90
Current Quarter Estimate	0.47
Most Accurate Estimate	0.47
Earnings ESP	0.00%
Next Earnings Report Date	07-25-2013
EPS Last Year	1.88
Expected Earnings Growth	26.23%

Username: Password:

Remember me [?]

Gilead Sciences Inc: (NASD: GILD)

$56.36

0.11 (0.20%)

Volume 16,625,910

May 15 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations